SCHEMBL24975723

SCHEMBL24975723

COc1cc2ncc(-c3cncc(N[C@H]4CNC[C@@H]4F)n3)n2nc1C1CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 4/20 0.39
▸ CLK2 P49760 2/20 0.39
▸ CLK3 P49761 2/20 0.39
▸ GSK3B P49841 2/20 0.39
▸ FLT3 P36888 12/20 0.38
▸ NRAS P01111 10/20 0.38
▸ IRAK1 P51617 3/20 0.37
▸ IRAK4 Q9NWZ3 3/20 0.37
▸ PDGFRB P09619 2/20 0.37
▸ CDK7 P50613 2/20 0.37
▸ CCNH P51946 2/20 0.37
▸ LCK P06239 1/20 0.37
▸ RET P07949 1/20 0.37
▸ CHEK2 O96017 1/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ PDGFRA P16234 1/20 0.34
▸ FLT4 P35916 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ DDR1 Q08345 1/20 0.34
▸ NTRK3 Q16288 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24975696 0.93 FLT3 (0.42) DYRK1ACLK2CLK3GSK3BFLT3
SCHEMBL27362603 0.93 FLT3 (0.42) DYRK1ACLK2CLK3GSK3BFLT3
SCHEMBL27362503 0.93 FLT3 (0.42) DYRK1ACLK2CLK3GSK3BFLT3
SCHEMBL31000281 0.92 DYRK1A (0.37) DYRK1ACLK2CLK3GSK3BFLT3
SCHEMBL27327094 0.90 FLT3 (0.41) DYRK1ACLK2CLK3FLT3NRAS
SCHEMBL27330963 0.90 FLT3 (0.41) DYRK1ACLK2CLK3FLT3NRAS
SCHEMBL24542508 0.89 FLT3 (0.38) FLT3NRASIRAK1IRAK4PDGFRB
SCHEMBL24542224 0.89 FLT3 (0.51) FLT3NRASIRAK1IRAK4PDGFRB
SCHEMBL27331176 0.89 FLT3 (0.38) FLT3NRASIRAK1IRAK4PDGFRB
SCHEMBL27331063 0.89 FLT3 (0.38) FLT3NRASIRAK1IRAK4PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154144-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDRENS HOSPITAL MED CT (US) 2025-05-15 — — US disclosed
WO-2023009833-A9 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-11-23 — — WO disclosed
WO-2023009833-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-02-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154144-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF FLT3, IRAK1, IRAK3 DYRK1A 694/4885CLK2 1630/4885CLK3 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback